Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
41 hedge funds and large institutions have $67.3M invested in Cellular Biomedicine Group, Inc. in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 17 reducing their positions, and 5 closing their positions.
5% less funds holding
Funds holding: 43 → 41 (-2)
6% less capital invested
Capital invested by funds: $71.7M → $67.3M (-$4.4M)
11% less call options, than puts
Call options by funds: $232K | Put options by funds: $260K
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
35% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
+$2.27M |
| 2 |
JP Morgan Chase
New York
|
+$552K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$126K |
| 4 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
+$100K |
| 5 |
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
|
+$70.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$2.65M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
-$907K |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$907K |
| 4 |
Two Sigma Investments
New York
|
-$341K |
| 5 |
Morgan Stanley
New York
|
-$255K |
CBMG Hedge Fund Activity: Q1 2020 in Review
41 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q1 2020, worth a combined $67.3M — down 6.1% from $71.7M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CBMG and 4 opened new positions — a net loss of 1 holder — while 17 trimmed existing stakes and 11 added.
The largest buyer was Man Group, opening a new position worth an estimated $2.27M. The largest seller was Platinum Investment Management, cutting an estimated $2.65M.
- 41 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q1 2020, down from 43 in Q4 2019.
- Funds reported $67.3M of Cellular Biomedicine Group, Inc. stock for Q1 2020, down 6.1% quarter-over-quarter.
- 4 funds opened new Cellular Biomedicine Group, Inc. positions in Q1 2020 and 5 closed out, a net change of -1 holder.
- The largest Cellular Biomedicine Group, Inc. buyer in Q1 2020 was Man Group, an estimated $2.27M added.
- The largest Cellular Biomedicine Group, Inc. seller in Q1 2020 was Platinum Investment Management, an estimated $2.65M sold.
Based on aggregated 13F filings for Q1 2020.